

**MYÉLOME
CANADA**



**MYELOMA
CANADA**

Uniquely devoted to the Canadian myeloma community

Thalomid® approved for funding in Quebec

Quebec, June 01, 2011

Effective June 1, Thalomid® (thalidomide) was listed in the Province of Quebec as a “medicament d’exception”, for the treatment of multiple myeloma in first line therapy in combination with melphalan and prednisone (MPT) for patients with multiple myeloma.

The new governmental body, INESSS (Institut national d’excellence en santé et en services sociaux), that replaced the “Conseil du médicament”, now includes a very detailed review document available on-line for each of the products it has reviewed, including positive and negative recommendations. For those that are interested in seeing the full document (available only in French), please see pages 53-60 of the attached -

http://www.inesss.qc.ca/fileadmin/doc/cdm/CapsulesAvis/_W_AvisMinistre_11_06.pdf.